Mojgan Ahmadzadeh

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
    Mojgan Ahmadzadeh
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Blood 114:1537-44. 2009
  2. pmc Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy
    Jianping Huang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 176:7726-35. 2006
  3. pmc IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells
    Mojgan Ahmadzadeh
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 30:294-302. 2007
  4. pmc FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions
    Mojgan Ahmadzadeh
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 112:4953-60. 2008
  5. doi request reprint Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma
    Alena Gros
    National Cancer Institute, Bethesda, MD, USA
    Clin Cancer Res 18:5212-23. 2012
  6. pmc Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells
    Takashi Inozume
    Surgery Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
    J Immunother 33:956-64. 2010
  7. pmc Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo
    Daniel J Powell
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 179:4919-28. 2007
  8. pmc Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer
    Xin Yao
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 119:5688-96. 2012
  9. pmc Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy
    Daniel J Powell
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    J Immunother 30:438-47. 2007
  10. pmc TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells
    Mojgan Ahmadzadeh
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:5215-23. 2005

Detail Information

Publications13

  1. pmc Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
    Mojgan Ahmadzadeh
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Blood 114:1537-44. 2009
    ..These findings suggest that the tumor microenvironment can lead to up-regulation of PD-1 on tumor-reactive T cells and contribute to impaired antitumor immune responses...
  2. pmc Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy
    Jianping Huang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 176:7726-35. 2006
    ..004) with the ability of these TILs to mediate tumor regression following adoptive transfer...
  3. pmc IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells
    Mojgan Ahmadzadeh
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 30:294-302. 2007
    ....
  4. pmc FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions
    Mojgan Ahmadzadeh
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 112:4953-60. 2008
    ....
  5. doi request reprint Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma
    Alena Gros
    National Cancer Institute, Bethesda, MD, USA
    Clin Cancer Res 18:5212-23. 2012
    ..Myeloid-derived suppressor cells (MDSC) have emerged as an immune-regulatory cell type that is expanded in tumor-bearing mice, but less is known about their immune-suppressive role in patients with cancer...
  6. pmc Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells
    Takashi Inozume
    Surgery Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
    J Immunother 33:956-64. 2010
    ..As a consequence, the PD-1 receptor can be a useful biomarker for enriching tumor-specific T cells from fresh melanomas...
  7. pmc Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo
    Daniel J Powell
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 179:4919-28. 2007
    ....
  8. pmc Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer
    Xin Yao
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 119:5688-96. 2012
    ..All 5 clinical trials are registered at www.clinicaltrials.gov as NCT00001832, NCT00096382, NCT00335127, NCT00509496, and NCT00513604...
  9. pmc Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy
    Daniel J Powell
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    J Immunother 30:438-47. 2007
    ....
  10. pmc TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells
    Mojgan Ahmadzadeh
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:5215-23. 2005
    ....
  11. pmc IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    J Immunother 29:313-9. 2006
    ..These studies suggest an important role for interleukin-7 in the treatment of patients with lymphopenia...
  12. pmc IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients
    Mojgan Ahmadzadeh
    Surgery Branch, NCI, NIH, Bethesda, MD 20892, USA
    Blood 107:2409-14. 2006
    ..Our findings suggest that selective inhibition of IL-2-mediated enhancement of regulatory T cells may improve the therapeutic effectiveness of IL-2 administration...
  13. pmc Interleukin-2-dependent mechanisms of tolerance and immunity in vivo
    Paul A Antony
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 176:5255-66. 2006
    ..Lastly, administration of anti-IL-2 plus exogenous IL-15 to tumor-bearing mice enhanced the adoptive immunotherapy of cancer. Therefore, Th cell-derived IL-2 paradoxically controls both tolerance and immunity to a tumor/self-Ag in vivo...